Dyne Therapeutics, Inc. DYN R2KR3KPHARMA
Company Overview
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.33.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +98.37% |
| 6 Months: | +63.39% |
| 3 Months: | +42.49% |
| 1 Month: | -6.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DYN Dyne Therapeutics, Inc. R2KR3KPHARMA | 24.28 | -7.45 | $4.53B | 0.00% | -41.20% | -81.57% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -3.63M | -7.85M | -8.68M | -13.52M | -25.13M | -30.16M | -42.77M | -35.78M | -52.76M | -42.28M | -45.46M | -66.74M | -62.27M | -69.16M | -71.96M | -105.57M | -122.37M | -115.79M | -113.89M | -125.28M | -181.66M |
| Net Income | -2.09M | -1.50M | -5.87M | -7.89M | -8.98M | -13.92M | -24.97M | -29.95M | -42.58M | -35.58M | -52.30M | -41.38M | -44.19M | -64.90M | -60.21M | -65.65M | -65.10M | -97.12M | -115.36M | -110.86M | -108.04M | -120.85M | -178.56M |
| Diluted EPS | - | - | - | - | - | - | - | -0.58 | -0.83 | -0.69 | -1.01 | -0.80 | -0.78 | -1.08 | -0.99 | -0.81 | -0.70 | -0.96 | -1.05 | -0.97 | -0.76 | -0.73 | -1.08 |
| R&D Expense | - | - | 2.98M | 6.09M | 7.33M | 9.68M | 18.62M | 23.87M | 36.51M | 28.24M | 46.66M | 34.67M | 37.54M | 59.13M | 55.25M | 44.54M | 62.26M | 92.80M | 106.45M | 99.24M | 97.22M | 100.89M | 152.17M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | -13.83M | -58.65M | -150.03M | -170.96M | -242.16M | -343.89M | -468.18M |
| Net Income | -14.86M | -59.44M | -149.29M | -168.10M | -235.94M | -317.42M | -446.21M |
| Diluted EPS | - | - | -2.93 | -3.23 | -3.95 | -3.37 | -3.47 |
| R&D Expense | 11.04M | 45.20M | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 16.44M | 353.33M | 425.66M | 306.32M | 165.08M | 691.23M | 1.19B |
| Total Equity | -4.88M | 14.04M | 342.37M | 368.20M | 252.36M | 91.29M | 629.84M | 972.13M |
| Cash & Equivalents | - | 14.63M | 300.85M | 200.82M | 172.15M | 121.63M | 435.45M | 893.37M |
| Long Term Debt | - | - | - | - | - | - | 0 | 148.92M |
| Total Liabilities | - | 2.40M | 10.97M | 57.47M | 53.96M | 73.79M | 61.40M | 214.83M |
| Current Liabilities | - | 2.36M | 10.97M | 28.72M | 28.09M | 51.09M | 42.26M | 50.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.83M | -46.51M | -119.56M | -153.65M | -188.16M | -292.37M | -403.21M |
| Investing Cash Flow | -1.65M | -45.66M | -137.89M | 87.20M | 83.31M | -204.08M | -28.75M |
| Financing Cash Flow | 19.99M | 380.69M | 157.82M | 37.39M | 54.32M | 809.89M | 890.31M |
| Capital Expenditure | -1.65M | -1.16M | -3.62M | -3.07M | -729.00K | -2.38M | -1.92M |
| Free Cash Flow | -13.48M | -47.67M | -123.18M | -156.71M | -188.89M | -294.75M | -405.13M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -105.9% | -17.4% | -40.5% | -66.6% | -258.4% | -50.4% | -45.9% |
| ROCE % | -98.2% | -17.1% | -37.8% | -61.4% | -212.4% | -53.0% | -41.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 16.55% | 30.91M | $774.97M |
| 2 | Blackrock Inc. | 6.64% | 12.40M | $310.98M |
| 3 | Jupiter Topco LLC | 6.42% | 12.00M | $300.78M |
| 4 | FMR, LLC | 6.00% | 11.21M | $280.96M |
| 5 | State Street Corporation | 3.99% | 7.46M | $186.98M |
| 6 | Orbis Allan Gray Ltd | 3.75% | 7.01M | $175.65M |
| 7 | Atlas Venture Life Science Advisors, LLC | 3.64% | 6.80M | $170.48M |
| 8 | Vanguard Capital Management LLC | 3.38% | 6.31M | $158.22M |
| 9 | TCG Crossover Management, LLC | 2.47% | 4.62M | $115.70M |
| 10 | Vanguard Portfolio Management LLC | 2.17% | 4.05M | $101.49M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DYN
Dyne Therapeutics (NASDAQ: DYN) officer plans $121,745 share sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQSmdLYjhUYVBUcHhieGd4TGstY015WUJ0cFhIcFl0OFM3cEJMOFVqRFp6ZU5QalFOb01mVmF3SFZKejJQVWhjeV9DOUJveXBwc2V4d2lKdFZ0bTA4ZUthVjM1SGVhMVBnaU1OUTdKbDM3aG9CNzc4b3FXYjBCeFNKSEc3aFl1VVRxc1JjOG…
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQUF9hUEdUckhKcGY1WFU3MW5RTHJCd05ZRjJScWJfVlBWYU40SDNERVZPVHg1M25VNU9TMVpmZDVkRHdwVnhPdWJiNXEwZ1Fvb2ZpRlk1Q1B2MDhoc3ZEUmpkWTl6QlVjeVJVVThBY2hIUlY4TFVfZk03NlNJZ2tRYmV6S3lJc2xp?oc=5"…
Why Dyne Therapeutics (DYN) Stock Is Down Today - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQd01WeWpkSERLdWphT19FbXRUSVlsVkpsTWNYZmJxT3A2N3dVN3BjaGZ2NzZzVGx6dXp1NnlucU40N1dNNXZtN0MwZ3VYV08wRkV6MUNHOGxSc3RhUkdhNW05U21KZE8zVU9PSXNRa1d5ekp5UlVmN3BVQ0JmWUVjUk9Jc2FQbGxuQ0dleg…
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQUXZINmxzaGplZGJQRGlDUnZMa01lY1VrUThiUW1UQ0o0OVVES3ZaZmpGMFdWZVdwWE1lRHBmODNyQTVSc0JPWmY5c2NSd2hzWFI2R2ZnN2x3WDZpbmNROG9TTUpsNU9lWEtPbGRJeE5McGFENW1kZTFqMWRfbzZwVmVsSWlyY0tfcTNKTG…
Dyne Therapeutics Stock Tumbles After Hours: Here's Why - Benzinga
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNeGxueXMxUWFzTEtMa0VqZG84bnhKVlpNMFhaS1hNSUNZRVllRnRqTENwcUtETkZ2V0ZsZ1YzLWRzZW45SUdmZWxfY3lTSmk0UUZNSkl3TFdiZVA4amV3WUtQaGNFVHFPM01RcXZQSEJ2ZEZWRllSY0NuSHRPUVlCQmZaU0U2Q2lxME5uT2…
Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNaEZVN3RIZm9OV25ySmhic055cVdmX3lnM19YaV9oZG41eXNqRXN3SkYtU2ZvU0p5ZWJpMVhkYVFLNVBwdGRXSWFBRXE0b3FEUnp4cU5Qb2YyQXVjRnFqYVVUdjktU2VvX3h5Z1VkTWgxUFdzakpCMzk2eXFJZmppdjlEVF9ZQ0dtU09UZW…
DYN — Frequently Asked Questions
What is the current share price of Dyne Therapeutics, Inc. (DYN)?
As of 2026-09-07 16:24 PDT, Dyne Therapeutics, Inc. (DYN) trades at $24.28 on NasdaqGS. Its 52-week range is $11.97 to $26.78.
What is the market capitalisation of DYN?
Dyne Therapeutics, Inc. (DYN) has a market capitalisation of $4.53B on NasdaqGS.
What is the P/E ratio of DYN?
DYN trades at a trailing price-to-earnings (P/E) ratio of -7.45. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.19.
What is the return on equity (ROE) of DYN?
DYN has a return on equity (ROE) of -81.57%. Its return on capital employed (ROCE) is -41.20%.
Is DYN a good stock to buy?
This page provides a data-driven analysis of Dyne Therapeutics, Inc. (DYN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.